Logo image of QTTB

Q32 BIO INC (QTTB) Stock Fundamental Analysis

NASDAQ:QTTB - Nasdaq - US7469641051 - Common Stock - Currency: USD

1.82  -0.08 (-4.21%)

After market: 1.82 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to QTTB. QTTB was compared to 559 industry peers in the Biotechnology industry. QTTB has a bad profitability rating. Also its financial health evaluation is rather negative. QTTB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

QTTB had negative earnings in the past year.
In the past year QTTB has reported a negative cash flow from operations.
In the past 5 years QTTB always reported negative net income.
In the past 5 years QTTB always reported negative operating cash flow.
QTTB Yearly Net Income VS EBIT VS OCF VS FCFQTTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -75.95%, QTTB is not doing good in the industry: 67.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -75.95%
ROE N/A
ROIC N/A
ROA(3y)-62.44%
ROA(5y)-56.27%
ROE(3y)-334.23%
ROE(5y)-224.95%
ROIC(3y)N/A
ROIC(5y)N/A
QTTB Yearly ROA, ROE, ROICQTTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

QTTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QTTB Yearly Profit, Operating, Gross MarginsQTTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QTTB has more shares outstanding
The number of shares outstanding for QTTB has been reduced compared to 5 years ago.
QTTB has a worse debt/assets ratio than last year.
QTTB Yearly Shares OutstandingQTTB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QTTB Yearly Total Debt VS Total AssetsQTTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.05, we must say that QTTB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.05, QTTB is not doing good in the industry: 63.86% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.05
ROIC/WACCN/A
WACC9.66%
QTTB Yearly LT Debt VS Equity VS FCFQTTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.60 indicates that QTTB has no problem at all paying its short term obligations.
The Current ratio of QTTB (4.60) is comparable to the rest of the industry.
QTTB has a Quick Ratio of 4.60. This indicates that QTTB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.60, QTTB is in line with its industry, outperforming 51.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
QTTB Yearly Current Assets VS Current LiabilitesQTTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.02% over the past year.
Looking at the last year, QTTB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)88.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.98%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, QTTB will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.93%
EPS Next 2Y32.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QTTB Yearly Revenue VS EstimatesQTTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M
QTTB Yearly EPS VS EstimatesQTTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QTTB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QTTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTTB Price Earnings VS Forward Price EarningsQTTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTTB Per share dataQTTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as QTTB's earnings are expected to grow with 18.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.74%
EPS Next 3Y18.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QTTB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Q32 BIO INC

NASDAQ:QTTB (6/9/2025, 8:00:01 PM)

After market: 1.82 0 (0%)

1.82

-0.08 (-4.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners74.57%
Inst Owner Change-6.42%
Ins Owners0.61%
Ins Owner Change22.48%
Market Cap22.20M
Analysts78
Price Target10.2 (460.44%)
Short Float %6.86%
Short Ratio3.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.47%
Min EPS beat(2)24.69%
Max EPS beat(2)28.26%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-33.54%
Max EPS beat(4)28.26%
EPS beat(8)3
Avg EPS beat(8)-70.48%
EPS beat(12)5
Avg EPS beat(12)-48.8%
EPS beat(16)9
Avg EPS beat(16)-32.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)2.04%
EPS NQ rev (1m)3.19%
EPS NQ rev (3m)-19.9%
EPS NY rev (1m)-2.26%
EPS NY rev (3m)-8.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.94
EYN/A
EPS(NY)-4.52
Fwd EYN/A
FCF(TTM)-5.33
FCFYN/A
OCF(TTM)-5.33
OCFYN/A
SpS0
BVpS-0.33
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.44%
ROA(5y)-56.27%
ROE(3y)-334.23%
ROE(5y)-224.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z -6.05
F-Score1
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)51.99%
Cap/Depr(5y)46.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.98%
EPS Next Y76.93%
EPS Next 2Y32.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.38%
OCF growth 3YN/A
OCF growth 5YN/A